Substance / Medication

Tolazamide

Overview

Active Ingredient
tolazamide
RxNorm CUI
10633

Indications

Tolazamide tablets are indicated as an adjunct to diet to lower the blood glucose in patients with noninsulin-dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone. In initiating treatment for noninsulin-dependent diabetes, diet should be emphasized as the primary form of treatment. Caloric restriction and weight loss are essential in the obese diabetic patient. Proper dietary management alone may be effective in controlling the blood glucose

Labeler: Mutual Pharmaceutical Company, IncUpdated: 2006-12-28T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Tolazamide tablets are contraindicated in patients with: 1) known hypersensitivity or allergy to tolazamide; 2) diabetic ketoacidosis, with or without coma. This condition should be treated with insulin; 3) Type I diabetes, as sole therapy. SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALI

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

903 trials linked to this intervention

903
Total Trials
103
Recruiting
282
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Model-Based Meta-Analysis of the Relationship Between Pioglitazone and Histological Outcomes in Metabolic Dysfunction-Associated Steatohepatitis Patients.
Tran Quyen Thi, Bui Tham Thi, Ngo Lien Thi et al. · CPT Pharmacometrics Syst Pharmacol · 2026
PMID: 40248984Meta-AnalysisFull text (PMC)
Prevalence of congenital anomalies in pregnancies complicated by type 2 diabetes: Systematic review and meta-analysis.
Oppermann Maria Lúcia R, Campos Maria Amélia A, Guerra Giulia L et al. · Int J Gynaecol Obstet · 2026
PMID: 40682407Meta-Analysis
Intensive Blood Pressure Control in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Cardiovascular and Microvascular Outcomes.
Mousavi Asma, Shojaei Shayan, Abhari Amir Parsa et al. · Am J Hypertens · 2026
PMID: 40717314Meta-Analysis
The Effect of SGLT2 Inhibitors on Blood Pressure in Relation to Baseline Kidney Function: A Systematic Literature Review and Data Analysis.
Møller Charlotte Agergaard, Nielsen Steffen Flindt, Mose Frank Holden · Am J Hypertens · 2026
PMID: 40717316Meta-Analysis
A meta-analysis of available data of the effects of selected whole and powdered fruits on glycemia in type 2 diabetes.
Kuramoto Nozomi, Hironaka Junya, Okada Hiroshi et al. · Am J Med · 2026
PMID: 40819727Meta-Analysis
Completing the picture of tolazamide polymorphism under extreme conditions: a low-temperature study.
Fedorov Alexey Yu, Rychkov Denis A, Losev Evgeniy A et al. · Acta Crystallogr C Struct Chem · 2019
PMID: 31062718Other
Isoenergetic Polymorphism: The Puzzle of Tolazamide as a Case Study.
Boldyreva Elena V, Arkhipov Sergey G, Drebushchak Tatiana N et al. · Chemistry · 2015
PMID: 26337712Other

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tolazamide (substance)
SNOMED CT
387186009
UMLS CUI
C0040372
RxNorm CUI
10633
Labeler
Mutual Pharmaceutical Company, Inc

Clinical Data

This intervention maps to 10 entities in the Healos knowledge graph.

1
Conditions
4
Biomarkers
3
Specialists
0
Symptoms
903
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.

Tolazamide — Conditions, Biomarkers & Specialists | Healos | Healos